title: Feasibility of measuring compliance to annual ivermectin treatment in the African Programme for Onchocerciasis Control.
abstract: The African Programme for Onchocerciasis Control (APOC) sponsors annual distribution of ivermectin to control onchocerciasis. Ivermectin should be taken annually by 65% of community members for a number of years to eliminate the disease as a public health problem. While many community coverage surveys have been undertaken during project monitoring, individual compliance could not be studied until several annual rounds of distribution had occurred. This paper reports on the efforts to determine whether adequate records could be found to enable a compliance study. A step-down process from project to district to community level was used to identify project sites where continuous ivermectin distribution up through 2004 had occurred. The first step consisted of selecting 17 of 25 projects by APOC. The second step determined adequacy of districts where distribution had occurred on a regular annual basis. Among 121 districts 58.6% undertook distribution in all 7 years. A total 852 villages were visited and community level records were found in all but three. Records showed that distribution had occurred for a minimum of five consecutive times in 429 villages, and ultimately 10 projects. While the feasibility study found an adequate number of villages to study compliance, the large number of projects, districts and villages that did not qualify for the follow-on compliance study should lead National Onchocerciasis Control Programme managers to strengthen the overall coverage and consistency of their efforts.
authors.affiliation: Department of International Health, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21014, USA. bbbrieger@jhsph.edu
authors.forename: William R
authors.initials: WR
authors.lastname: Brieger
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Okeibunor
authors.forename: Adenike O
authors.initials: AO
authors.lastname: Abiose
authors.forename: Richard
authors.initials: R
authors.lastname: Ndyomugyenyi
authors.forename: William
authors.initials: W
authors.lastname: Kisoka
authors.forename: Samuel
authors.initials: S
authors.lastname: Wanji
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Elhassan
authors.forename: Uche V
authors.initials: UV
authors.lastname: Amazigo
mesh_terms: D000293:Adolescent; D000328:Adult; D000349:Africa / Q000453:epidemiology; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D002648:Child; D003153:Community Health Services / Q000458:organization & administration; D003256:Community Participation; D005240:Feasibility Studies; D005260:Female; D019538:Health Care Surveys / Q000379:methods; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D008499:Medical Records; D009855:Onchocerciasis / Q000453:epidemiology / Q000517:prevention & control*; D010349:Patient Compliance; D012041:Regional Medical Programs / Q000458:organization & administration; D012423:Rural Health
chemical_list: D000977:Antiparasitic Agents; D007559:Ivermectin